

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

22 Jun 2026

### In- Vivo Bioequivalence study of Teriflunomide tablet 14 mg Abidi (GIOMIDE® 14 mg, Abidi, Iran) Pharma. with brand drug (AUBAGIO® 14 mg, Genzyme, Germany) in Iranian healthy volunteers.

#### Protocol summary

##### Study aim

In- Vivo Bioequivalence study of Teriflunomide tablet 14 mg Abidi Pharma. with brand drug (AUBAGIO® 14 mg, Genzyme, Germany) in Iranian healthy volunteers.

##### Design

In-vivo bioequivalence study of Teriflunomide tablet 14 mg Abidi Pharma. in compared with reference drug (AUBAGIO® 14 mg, Genzyme, Germany ). The single blind, Cross-over, two period, two groups (Intervention and control) and randomized (paper lottery randomization method) study with ten week wash-out time.

##### Settings and conduct

This study is carried out in Simin Baspar Tayf-Gostar Company, Tabriz, Iran. The study population is 24 healthy Iranian volunteers. This study is a single blind study and by taking out the drugs from the existing packaging, the volunteers will not know the time of receiving the test drug and the brand. This study is a cross over study that is performed in two time periods of 432 hours with a ten-week wash-out period.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: Age between 18-55 years, body mass index (BMI) in the range of 18-28. Exclusion criteria: History of heart, kidney and liver disease, Pregnancy, Drug addiction, Smoking

##### Intervention groups

Single dose Teriflunomide tablet 14 mg Abidi Pharma.  
Control group: brand drugs (AUBAGIO® 14 mg, Genzyme, Germany)

##### Main outcome variables

Plasma drug concentration

#### General information

##### Reason for update

##### Acronym

#### IRCT registration information

IRCT registration number: **IRCT20200105046010N47**

Registration date: **2021-12-18, 1400/09/27**

Registration timing: **registered\_while\_recruiting**

Last update: **2021-12-18, 1400/09/27**

Update count: **0**

#### Registration date

2021-12-18, 1400/09/27

#### Registrant information

##### Name

Javad Shokri

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 41 3661 4125

##### Email address

shokri.j@gmail.com

#### Recruitment status

**Recruitment complete**

#### Funding source

#### Expected recruitment start date

2021-12-07, 1400/09/16

#### Expected recruitment end date

2022-06-06, 1401/03/16

#### Actual recruitment start date

empty

#### Actual recruitment end date

empty

#### Trial completion date

empty

#### Scientific title

In- Vivo Bioequivalence study of Teriflunomide tablet 14 mg Abidi (GIOMIDE® 14 mg, Abidi, Iran) Pharma. with

brand drug (AUBAGIO® 14 mg, Genzyme, Germany) in Iranian healthy volunteers.

#### Public title

In-vivo Bioequivalence Test of Teriflunomide tablets with brand drug (AUBAGIO® 14 mg, Genzyme, Germany)

#### Purpose

Treatment

#### Inclusion/Exclusion criteria

##### Inclusion criteria:

General health Body mass index between 18-28 Informed consent Being at the age of 18-55 years old

##### Exclusion criteria:

Smoking A history of cardiovascular disease A history of liver & kidney disease Pregnancy Alcohol & Drug addiction Hypersensitivity to the drug

#### Age

From **18 years** old to **55 years** old

#### Gender

Both

#### Phase

Bioequivalence

#### Groups that have been masked

- Participant

#### Sample size

Target sample size: **24**

#### Randomization (investigator's opinion)

Randomized

#### Randomization description

For this purpose, A 24- persons group will be selected and divided to two 12-persons groups randomly. The names of all volunteers will be written on paper pieces and wrapped in aluminum foils. The first 12 papers will randomly be withdrawn from bottle will be selected as group A and others will be categorized in group B.

#### Blinding (investigator's opinion)

Single blinded

#### Blinding description

Candidates are not aware of receiving the test drug or brand one. In a one-blind study, information that could distort the test result is hidden from the candidates, but the person in charge of the test is aware of it. Test and Brand drugs are removed from their packaging by the executor and placed in similar and coded cans. Volunteers will not be informed about receiving the brand or test drug.

#### Placebo

Not used

#### Assignment

Crossover

#### Other design features

### Secondary Ids

empty

### Ethics committees

#### 1

Ethics committee

#### Name of ethics committee

Ethics Committee of Tabriz University of Medical Sciences

#### Street address

Third floor; Central building; Tabriz University of Medical Sciences; Dneshgah St.

#### City

Tabriz

#### Province

East Azarbaijan

#### Postal code

5166614766

#### Approval date

2021-11-29, 1400/09/08

#### Ethics committee reference number

IR.TBZMED.REC.1400.826

### Health conditions studied

#### 1

#### Description of health condition studied

Bio equivalence test

#### ICD-10 code

#### ICD-10 code description

### Primary outcomes

#### 1

#### Description

Plasma drug concentration

#### Timepoint

Sampling times in this study will be 0, 0:30, 1, 1:30, 2, 2:30, 3, 3:30, 4, 5, 6, 8, 10, 12, 24, 48, 72, 96, 144, 288, 432 hours after prescribing the tablet.

#### Method of measurement

High Performance Liquid Chromatography with tandem mass spectroscopy detector

### Secondary outcomes

empty

### Intervention groups

#### 1

#### Description

Intervention group: One test tablet (Teriflunomide tablet 14 mg produced by Abidi Pharma.) will be received. Blood samples will be taken for 432 hours at the mentioned times after drug administration and the concentration of the drug in Plasma samples will be measured by liquid chromatography with mass spectroscopy detector

#### Category

Treatment - Other

#### 2

#### Description

Control group: One Reference tablet (AUBAGIO® 14 mg, Genzyme, Germany) will be received. Blood samples will be taken for 432 hours at the mentioned times after drug administration and the concentration of Teriflunomide in plasma samples will be measured by liquid chromatography with mass spectroscopy detector.

#### Category

Treatment - Other

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Simin Baspar Teyf Gostar Company

##### Full name of responsible person

Javad Shokri

##### Street address

No.48, Ferdos square

##### City

Tabriz

##### Province

East Azarbaijan

##### Postal code

5167874434

##### Phone

+98 41 3384 2724

##### Email

Shokri.j@gmail.com

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Abidi Pharmaceutical Company

##### Full name of responsible person

Farzaneh Jalilopur

##### Street address

8th km of Shahid Lashkari highway, Karaj special road. Obaidi Boulevard No. 72

##### City

Tehran

##### Province

Tehran

##### Postal code

1389776363

##### Phone

+98 21 4452 2451

##### Email

info@abidi-diabetes.com

#### Grant name

#### Grant code / Reference number

#### Is the source of funding the same sponsor organization/entity?

Yes

#### Title of funding source

Abidi Pharmaceutical Company

#### Proportion provided by this source

100

#### Public or private sector

Private

#### Domestic or foreign origin

Domestic

#### Category of foreign source of funding

empty

#### Country of origin

#### Type of organization providing the funding

Persons

## Person responsible for general inquiries

#### Contact

##### Name of organization / entity

Tabriz University of Medical Sciences

##### Full name of responsible person

Javad Shokri

##### Position

Professor

##### Latest degree

Ph.D.

##### Other areas of specialty/work

Medical Pharmacy

##### Street address

Faculty of Pharmacy, Tabriz University of Medical Sciences, Daneshgah

##### City

Tabriz

##### Province

East Azarbaijan

##### Postal code

5166414766

##### Phone

+98 41 3334 8489

##### Email

Shokri.j@gmail.com

## Person responsible for scientific inquiries

#### Contact

##### Name of organization / entity

Tabriz University of Medical Sciences

##### Full name of responsible person

Javad Shokri

##### Position

Professor

##### Latest degree

Ph.D.

##### Other areas of specialty/work

Medical Pharmacy

##### Street address

Faculty of Pharmacy, Tabriz University of Medical Sciences, Daneshgah

##### City

Tabriz

##### Province

East Azarbaijan

##### Postal code

5166414766

##### Phone

+98 41 3334 8489

**Email**

Shokri.j@gmail.com

**Person responsible for updating data****Contact****Name of organization / entity**

Simin Baspar Teyf Gostar Company

**Full name of responsible person**

Dariush.omidfar

**Position**

Lab. Manager

**Latest degree**

Master

**Other areas of specialty/work**

Others

**Street address**

No.48, Ferdos square

**City**

Tabriz

**Province**

East Azarbaijan

**Postal code**

5167874434

**Phone**

+98 41 3384 2724

**Email**

Dariush.omidfar@gmail.com

**Sharing plan****Deidentified Individual Participant Data Set (IPD)**

No - There is not a plan to make this available

**Justification/reason for indecision/not sharing IPD**

These data are as secure between researcher and related industries

**Study Protocol**

No - There is not a plan to make this available

**Statistical Analysis Plan**

No - There is not a plan to make this available

**Informed Consent Form**

No - There is not a plan to make this available

**Clinical Study Report**

No - There is not a plan to make this available

**Analytic Code**

No - There is not a plan to make this available

**Data Dictionary**

Yes - There is a plan to make this available

**Title and more details about the data/document**

Only protocol and methods of study are sharable

**When the data will become available and for how long**

Only protocol and methods of study are shareable.

**To whom data/document is available**

Pharmaceutical and medical sciences researchers

**Under which criteria data/document could be used**

Projects information's for any publications is not allowed.

**From where data/document is obtainable**

By email to the project manager (shokri.j@gmail.com)

**What processes are involved for a request to access data/document**

This information is confidential and is at the disposal of the project sponsor. Upon request, the information will be provided to the applicant by the contractor's email after the

**Comments**